Moorestown, New Jersey, United States
biotecNOVA® Medicines
Cancer Meds
SELECT A TYPE OF CANCER
- Advanced non–small cell lung cancer
- Melanoma
- Head and neck squamous cell cancer
- High-risk non-muscle invasive bladder cancer (NMIBC)
- Advanced urothelial bladder cancer
- Advanced kidney cancer (RCC)
- Advanced MSI-H/dMMR colorectal cancer
- Microsatellite instability-high cancer (MSI-H/dMMR)
- High-risk early-stage triple-negative breast cancer (TNBC)
- Advanced triple-negative breast cancer (TNBC)
- Classical Hodgkin lymphoma (cHL)
- Advanced gastric cancer
- Advanced cervical cancer
- Primary mediast
ADVANCED LUNG CANCER
NON-SMALL CELL LUNG CANCER
- OPDIVO + YERVOY for certain adults with newly diagnosed advanced non-small cell lung cancer that tests positive for PD-L1
- OPDIVO + YERVOY, in combination with chemotherapy, for adults with newly diagnosed advanced non-small cell lung cancer
- OPDIVO for people who have had prior treatments for non-small cell lung cancer
Choose your condition:
- Advanced Lung Cancer
- Advanced Kidney Cancer
- Advanced Liver Cancer
- Colorectal Cancer (MSI-H/dMMR)
- Gastric (Stomach), o
How do OPDIVO® (nivolumab) and YERVOY® (ipilimumab) team up to fight cancer differently than chemotherapy?
OPDIVO + YERVOY works by helping your immune system to fight cancer. It does this by combining 2 immunotherapy medications that work in different but complementary ways.
Together, OPDIVO and YERVOY can help your immune system launch a response against cancer that's greater than when either medication is used alone.
LIBTAYO is indicated for the first-line treatment of patients with non–small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (tumor proportion score [TPS] ≥50%) as determined by an FDA-approved test, with no EGFR, ALK, or ROS1 aberrations, and is locally advanced where patients are not candidates for surgical resection or definitive chemoradiation OR metastatic.
LIBTAYO is indicated for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally
IMFINZI is a prescription medicine used to treat adults with a type of lung cancer called non-small cell lung cancer (NSCLC). IMFINZI may be used when your NSCLC has not spread outside your chest, cannot be removed by surgery, and has responded or stabilized with initial treatment with chemotherapy that contains platinum, given at the same time as radiation therapy.
LENVIMA® (lenvatinib) is a prescription medicine that is used to treat people with certain kinds of cancer.
- LENVIMA is used by itself to treat differentiated thyroid cancer (DTC), a type of thyroid cancer that can no longer be treated with radioactive iodine and is progressing.
- LENVIMA is used along with another medicine called everolimus to treat adults with a type of kidney cancer called advanced renal cell carcinoma (RCC) after one course of treatment with another anti-cancer medicine.
- LENVIMA
TECENTRIQ MAY WORK WITH YOUR IMMUNE SYSTEM TO FIGHT CANCER
PLEASE SELECT CANCER TYPE:
TRODELVY® (sacituzumab govitecan-hziy) is a prescription medicine used to treat adults with:
- triple-negative breast cancer (negative for estrogen and progesterone hormone receptors and HER2) that has spread to other parts of the body (metastatic) or cannot be removed by surgery, and who have received two or more prior treatments, including at least one treatment for metastatic disease.
- bladder cancer and cancers of the urinary tract that have spread or cannot be removed by surgery, and who have r
A new era in the treatment of people with HR+, HER2–, node-positive, early breast cancer with a high risk of coming back, or certain types of HR+, HER2– metastatic breast cancer
LYNPARZA is the only PARP inhibitor approved for the following 4 types of advanced cancer:
For use in select patients:
ADVANCED OVARIAN CANCERMETASTATIC PROSTATE CANCERMETASTATIC PANCREATIC CANCERMETASTATIC BREAST CANCER
VENCLEXTA is a prescription medicine used:
- to treat adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
- in combination with azacitidine, or decitabine, or low-dose cytarabine to treat adults with newly diagnosed acute myeloid leukemia (AML) who:
- are 75 years of age or older, or
- have other medical conditions that prevent the use of standard chemotherapy.
IMBRUVICA® (ibrutinib) is a prescription medicine used to treat adults with:
- Mantle cell lymphoma (MCL) who have received at least one prior treatment
- Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL)
- Chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion
- Waldenström’s macroglobulinemia (WM)
- Marginal zone lymphoma (MZL) who require a medicine by mouth or injection (systemic therapy) and have received a certain type of prior treatment
- Chronic graft ver
In a clinical study, CABOMETYX was given to people with advanced kidney cancer as a first treatment (your doctor may call it “first-line treatment”), with another medicine, OPDIVO
CABOMETYX is a prescription medicine used to treat:
- People with kidney cancer (renal cell carcinoma). CABOMETYX may be used:
- Alone to treat people with renal cell carcinoma (RCC) that has spread (advanced RCC)
- In combination with nivolumab when your cancer has spread (advanced RCC), and you have not already had treatment for your advanced RCC
- People with liver cancer (hepatocellular carcinoma) who have been previously treated with the medicine sorafenib.
- Adults and children 12 years of age and older
XTANDI is a prescription medicine used to treat men with prostate cancer that:
- no longer responds to a hormone therapy or surgical treatment to lower testosterone
- OR
- has spread to other parts of the body and responds to a hormone therapy or surgical treatment to lower testosterone
CALQUENCE is a prescription medicine used to treat adults with mantle cell lymphoma (MCL) who have received at least one prior treatment for their cancer, or adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
XALKORI® (crizotinib) is a prescription medicine used to treat people with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in either a gene called ALK (anaplastic lymphoma kinase) or a gene called ROS1
ZEJULA is a prescription medicine used for the:
- maintenance treatment of adults with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. ZEJULA is used after the cancer has responded (complete or partial response) to treatment with platinum-based chemotherapy
- maintenance treatment of adults with ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that comes back. ZEJULA is used after the cancer has responded (complete or partial response) to treatment with
What is TUKYSA?
TUKYSA is a prescription medicine used with the medicines trastuzumab and capecitabine to treat adults with human epidermal growth factor receptor-2 (HER2) positive breast cancer that has spread to other parts of the body such as the brain (metastatic), or that cannot be removed by surgery, and who have received one or more anti-HER2 breast cancer treatments.
It is not known if TUKYSA is safe and effective in children.
WHAT IS PADCEV®?
PADCEV is a prescription medicine used to treat adults with bladder cancer and cancers of the urinary tract (renal pelvis, ureter or urethra) that has spread or cannot be removed by surgery. PADCEV may be used if you:
• have received an immunotherapy medicine and chemotherapy that contains platinum, or
• you are not able to receive a chemotherapy that contains the medicine cisplatin and you have received one or more prior therapy.
It is not known if PADCEV is safe and effective in
What is ENHERTU?
ENHERTU (en-HER-too) is a prescription medicine used in adults to treat human epidermal growth factor receptor 2 (HER2)-positive:
- Breast cancer that cannot be removed by surgery or that has spread to other parts of your body (metastatic), and who have received two or more prior anti-HER2 breast cancer treatments.
ENHERTU was FDA approved for this use based on a clinical study that measured how many patients responded and how long they responded. ENHERTU is still being studied t
YESCARTA is a treatment for your large B-cell lymphoma or follicular lymphoma, two types of non-Hodgkin lymphoma. It is used when at least two other kinds of treatment have failed to control your cancer. YESCARTA is different than other cancer medicines because it is made from your own white blood cells, which have been modified to recognize and attack your lymphoma cells.
Indication
BREYANZI is for the treatment of large B-cell lymphoma in patients when at least 2 previous treatments have not worked or have stopped working. BREYANZI is a medicine made from your own white blood cells; the cells are genetically modified to recognize and attack your lymphoma cells.
Metastatic Merkel cell carcinoma (MCC)
- BAVENCIO® (avelumab) is indicated for the treatment of adults and pediatric patients 12 years and older with metastatic MCC. This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials
First-line maintenance treatment of urothelial carcinoma (UC)
- BAVENCIO is indicated
BRUKINSA is a prescription medicine used to treat adults with:
- Waldenström’s macroglobulinemia (WM).
- Mantle cell lymphoma (MCL) who have received at least one prior treatment for their cancer.
- Marginal zone lymphoma (MZL) when the disease has come back or did not respond to treatment and who have received at least one certain type of treatment.
RETEVMO is a prescription medicine that is used to treat certain cancers caused by an abnormal gene, called RET, in:
- adults with non-small cell lung cancer (NSCLC) that has spread.
- adults and children 12 years of age and older with advanced medullary thyroid cancer (MTC) or MTC that has spread, who need a medicine that can be taken by mouth or injection.
- adults and children 12 years of age and older with advanced thyroid cancer or thyroid cancer that has spread,
RYBREVANT® is a prescription medicine used to treat adults with non-small cell lung cancer (NSCLC) that:
- has spread to other parts of the body (metastatic) or cannot be removed by surgery, and
- has a certain abnormal epidermal growth factor receptor “EGFR” gene(s) and
- whose disease has worsened while on or after chemotherapy that contains platinum.
SARCLISA is a prescription medicine used in combination with:
- The medicines pomalidomide and dexamethasone, to treat adults who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor to treat multiple myeloma.
- The medicines carfilzomib and dexamethasone, to treat adults with multiple myeloma who have already received 1 to 3 lines of treatment and they did not work or are no longer working.
What is KYMRIAH?
KYMRIAH is made from your own white blood cells and is a prescription cancer treatment used in patients up to 25 years old who have acute lymphoblastic leukemia (ALL) that is either relapsing (went into remission, then came back) or is refractory (did not go into remission after receiving other leukemia treatments). It is also used in patients with non-Hodgkin lymphoma that has relapsed or is refractory after having at least two other kinds of treatment.
Heart Meds
12
12
XARELTO® is a prescription medicine used to:
- reduce the risk of stroke and blood clots in people who have a medical condition called atrial fibrillation that is not caused by a heart valve problem. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to the formation of blood clots, which can travel to the brain, causing a stroke, or to other parts of the body
- treat blood clots in the veins of your legs (deep vein thrombosis or DVT) or lungs (pulmonary emboli
12
12
12
BiotecNOVA meds have completed proven and successful clinical trials
biotecNOVA® Medicines
Diabetic Meds & Med-Tech
12
12
What is FARXIGA?
FARXIGA is a prescription medicine used to:
- improve blood sugar control along with diet and exercise in adults with type 2 diabetes
- reduce the risk of hospitalization for heart failure in adults with type 2 diabetes and known cardiovascular disease or multiple cardiovascular risk factors
- reduce the risk of cardiovascular death and hospitalization for heart failure in adults with symptomatic heart failure (when the heart is weak and cannot pump enough blood to the rest of your body)
12
12
12
Cystic Fibrosis Meds
12
12
12
12
12
12
BiotecNOVA meds have completed proven and successful clinical trials